Netarsudil/latanoprost fixed-dose combination for the treatment of
open-angle glaucoma or ocular hypertension

Radell, Jake E; Serle, Janet B.

doi:10.1358/dot.2019.55.9.3039670

Cited by 6 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One may nonetheless be bothered by frequent adverse effects: blepharitis, conjunctival hyperemia, subconjunctival hemorrhages, cornea verticillata type corneal opacities [88,91,92]. The combination of a ROCK inhibitor with a prostaglandin has been proposed and appears to obtain synergistic results on IOP lowering, with IOP reductions of 30% or more seen in 59 to 65% of subjects treated with the combination of netarsudil and latanoprost, vs. 29 to 37% of subjects treated with latanoprost alone and 21 to 29% of subjects treated with netarsudil alone (p<0.0001) [93,94].…”

Section: Medical Approachmentioning

confidence: 99%

The trabecular meshwork: Structure, function and clinical implications. A review of the literature

Buffault

Labbé

Hamard

et al. 2020

Journal Français d'Ophtalmologie

View full text Add to dashboard Cite

Glaucoma is a blinding optic neuropathy, the main risk factor for which is increased intraocular pressure (IOP). The trabecular meshwork, located within the iridocorneal angle, is the main pathway for drainage of aqueous humor (AH) out of the eye, and its dysfunction is responsible for the IOP elevation. The trabecular meshwork is a complex, fenestrated, threedimensional structure composed of trabecular meshwork cells (TMC) interdigitated into a multilayered organization within the extracellular matrix (ECM). The purpose of this literature review is to provide an overview of current understanding of the trabecular meshwork and its pathophysiology in glaucoma. Thus, we will present the main anatomical and cellular bases for the regulation of aqueous humor outflow resistance, the pathophysiological mechanisms involved in trabecular dysfunction in the various types of glaucoma, as well as current and future therapeutic strategies targeting the trabecular meshwork.

show abstract